- Home
- STRO vs VNDA Comparison
STRO vs VNDA Comparison
Compare STRO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | VNDA |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 398.9M |
| IPO Year | 2018 | 2006 |
Fundamental Metrics
Financial Performance| Metric | STRO | VNDA |
|---|---|---|
| Price | $11.18 | $7.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $18.29 | $14.00 |
| AVG Volume (30 Days) | 125.6K | ★ 1.3M |
| Earning Date | 11-06-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $105,646,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $63.08 | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $5.23 | $3.81 |
| 52 Week High | $21.50 | $7.25 |
Technical Indicators
Market Signals| Indicator | STRO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 79.18 | 70.22 |
| Support Level | $8.49 | $6.75 |
| Resistance Level | $12.00 | $7.20 |
| Average True Range (ATR) | 0.83 | 0.43 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 78.61 | 97.46 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.